Combined SFK/mTOR Inhibition Prevents Rapamycin-Induced Feedback Activation of AKT and Elicits Efficient Tumor Regression
- 1 September 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (17) , 4762-4771
Abstract
Resistance to receptor tyrosine kinase (RTK) blockade in breast cancer is often mediated by activation of bypass pathways that sustain growth. Src and mammalian target of rapamycin (mTOR) are two intrinsic targets that are downstream of most RTKs. To date, limited clinical efficacy has been observed with either Src or mTOR inhibitors when used as single agents. Resistance to mTOR inhibitors is associated with loss of negative feedback regulation, resulting in phosphorylation and activation of AKT. Herein, we describe a novel role for Src in contributing to rapalog-induced AKT activation. We found that dual activation of Src and the mTOR pathway occurs in nearly half of all breast cancers, suggesting potential cross-talk. As expected, rapamycin inhibition of mTOR results in feedback activation of AKT in breast cancer cell lines. Addition of the Src/c-Abl inhibitor, dasatinib, completely blocks this feedback activation, confirming convergence between Src and the mTOR pathway. Analysis in vivo revealed that dual Src and mTOR inhibition is highly effective in two mouse models of breast cancer. In a luminal disease model, combined dasatinib and rapamycin is more effective at inducing regression than either single agent. Furthermore, the combination of dasatinib and rapamycin delays tumor recurrence following the cessation of treatment. In a model of human EGFR-2–positive (HER2+) disease, dasatinib alone is ineffective, but potentiates the efficacy of rapamycin. These data suggest that combining mTOR and Src inhibitors may provide a new approach for treating multiple breast cancer subtypes that may circumvent resistance to targeted RTK therapies. Cancer Res; 74(17); 4762–71. ©2014 AACR.Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Dasatinib inhibits mammary tumour development in a genetically engineered mouse modelThe Journal of Pathology, 2013
- Receptor association and tyrosine phosphorylation of S6 kinasesThe FEBS Journal, 2006
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates AktCancer Research, 2006
- Balancing Akt with S6KJournal of Cell Biology, 2004
- Determinants of Rapamycin Sensitivity in Breast Cancer CellsClinical Cancer Research, 2004
- Src family kinases in tumor progression and metastasisCancer and Metastasis Reviews, 2003
- Interaction between Src and a C-terminal Proline-rich Motif of Akt Is Required for Akt ActivationJournal of Biological Chemistry, 2003
- PI3‐kinase in concert with Src promotes the S‐phase entry of oestradiol‐stimulated MCF‐7 cellsThe EMBO Journal, 2001
- Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.Molecular and Cellular Biology, 1992
- Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogeneCell, 1988